CYLD Rabbit Polyclonal Antibody

CAT#: TA351116

Rabbit Polyclonal Anti-CYLD Antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (4)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human cylindromatosis (turban tumor syndrome) (CYLD), transcript variant 2, 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Transient overexpression lysate of cylindromatosis (turban tumor syndrome) (CYLD), transcript variant 2
    • 100 ug

CNY 3,080.00


Recombinant protein of human cylindromatosis (turban tumor syndrome) (CYLD), transcript variant 1, 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Applications IHC
Recommend Dilution IHC: 50-200
Positive control: Human gasrtic cancer
Predicted cell location: Cytoplasm
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide of human CYLD
Formulation pH7.4 PBS, 0.05% NaN3, 40% Glyceroln
Concentration lot specific
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name CYLD lysine 63 deubiquitinase
Background This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Synonyms BRSS; CDMT; CYLD1; CYLDI; EAC; MFT; MFT1; SBS; TEM; USPL2
Reference Data
Protein Families Druggable Genome
Protein Pathways RIG-I-like receptor signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...